complete cytogenetic response
Showing 1 - 25 of >10,000
CharactHer. ICORG 12-09, V3
Terminated
- HER2-positive Breast Cancer
- TNM Stage II-IV Breast Cancer
-
Dublin, Ireland
- +1 more
Jan 14, 2022
Leukemia, Myeloid, Chronic-Phase Trial in Bordeaux (Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet,
Terminated
- Leukemia, Myeloid, Chronic-Phase
- Imatinib Mesylate 600 MG Oral Tablet
- +2 more
-
Bordeaux, Aquitaine, FranceInstitut Bergonié
Dec 30, 2020
Chronic Myelogenous Leukemia Trial in Beirut (Nilotinib)
Recruiting
- Chronic Myelogenous Leukemia
-
Beirut, LebanonAmerican University of Beirut Medical Center
Feb 14, 2022
t Pathologic Complete Response Observed in HER2 Positive Breast
Completed
- HER2+ Breast Cancer
-
Rawalpindi, Punjab, PakistanRawalpindi Medical University
Jun 26, 2023
Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
Recruiting
- Non-small Cell Lung Cancer
- +2 more
- CT/PET/WSI-based Deep Learning Signature
-
Zunyi, Guizhou, China
- +2 more
Jun 27, 2023
MRI Criterion After Neoadjuvant Therapy in Locally Advanced
Completed
- Rectal Neoplasms
-
Nîmes, Gard, FranceChu de Nîmes
Sep 8, 2022
Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy Trial in Nanjing (Stained region
Recruiting
- Axillary Lymph Node Dissection
- +4 more
- Stained region Lymph Node Biopsy (SrLNB)
- Regional lymph node radiotherapy (RNI) including the axilla
-
Nanjing, ChinaThe First Affiliated Hospital of Nanjing Medical University
Jul 10, 2023
Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response
Recruiting
- Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
- Vacuum-assisted biopsy
-
Saint-Petersburg, Russian FederationPetr Krivorotko
Jun 14, 2022
Inflammatory Breast Cancer Trial (Breast conserving surgery, Radical modified mastectomy)
Not yet recruiting
- Inflammatory Breast Cancer
- Breast conserving surgery
- Radical modified mastectomy
- (no location specified)
Nov 14, 2023
Breast Cancer Trial (Omission of radiotherapy)
Not yet recruiting
- Breast Cancer
- Omission of radiotherapy
- (no location specified)
Jun 8, 2022
Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III Trial in Guangzhou (drug, radiation, procedure, other)
Recruiting
- Rectal Cancer
- +3 more
- Capecitabine, Oxaliplatin
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 19, 2022
ASCT Versus Chemotherapy as First-Line Consolidation Therapy
Completed
- T-cell Lymphoma Adults
- consolidation with ASCT
- (no location specified)
Nov 25, 2023
Early Predict Pathological Complete Response to Neoadjuvant
Recruiting
- Breast Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Aug 8, 2022
Locally Advanced Basal Cell Carcinoma Trial in Brescia (Sonidegib)
Recruiting
- Locally Advanced Basal Cell Carcinoma
-
Brescia, ItalyAsst Degli Spedali Civili Di Brescia
Aug 3, 2022
Predictive Factor of Pathologic Complete Response After
Completed
- Rectum Cancer
-
Bangkok, Bankok, ThailandChairat Supsamutchai
May 15, 2022
Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to
Active, not recruiting
- Esophageal Cancer
- follow up
-
Guangzhou, Guangdong, ChinaJianhua Fu
Sep 24, 2023
Head and Neck Squamous Cell Carcinoma Trial in Zhuhai (dose-reduced radiotherapy)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- dose-reduced radiotherapy
-
Zhuhai, Guangdong, ChinaFifth Affiliated Hospital of Sun Yat-sen University
May 3, 2023
Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,
Active, not recruiting
- Relapsed Ovarian Cancer
- +2 more
- Olaparib 300mg tablets
-
Beijing, China
- +24 more
Dec 5, 2022
PTCL Patients Who Achieved Complete Response From Frontline Treatment Trial (Selinexor)
Not yet recruiting
- PTCL Patients Who Achieved Complete Response From Frontline Treatment
- (no location specified)
Apr 18, 2023
Triple Negative Breast Tumors Trial (Xiaopi granules, Xiaopi decoction, Placebo)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Xiaopi granules
- +2 more
- (no location specified)
Nov 22, 2023
The ImmunoXXL Study
Recruiting
- Hepatocellular Carcinoma
- Liver Transplantation
-
Milano, MI, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
May 25, 2023
Breast Cancer Trial in United States (MRI Biopsy)
Recruiting
- Breast Cancer
- MRI Biopsy
-
Basking Ridge, New Jersey
- +6 more
Nov 23, 2022